Molecular Tumor Board
The Markey Cancer Center Molecular Tumor Board (MTB) is a statewide service available to physicians at UK HealthCare and regional affiliates.
The MTB provides a forum for expert clinicians, pathologists and scientists to discuss and analyze tumor genotypes and molecular abnormalities in order to recommend patient specific targeted therapies.
The MTB is intended to supplement oncology tumor boards and includes a broad range of expert panel members.
Clinicians can order a genomic report and submit a case study to be presented for review by the MTB during their twice monthly meetings. For an overview of the MTB, download the referral flyer below.
Leadership Contact Information
- Jill Kolesar, PharmD, MS, Co-Director
- Rachel Miller, MD, Co-Director
Molecular Tumor Board Office Phone: 1-844-622-0341
Abigail Anderson, PhD, firstname.lastname@example.org
MTB Project Manager
Rebecca Carpenter, email@example.com
Administrative Support Associate
The Molecular Tumor Board (MTB) meets:
- 12 p.m.
- Every first and third Tuesday
Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.
To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.
2022 MTB Meeting Schedule
|Month||Day / Tues||Location|
Continuing Medical Education (CME)
If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at firstname.lastname@example.org.
Policy on Disclosure
It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.
Cases must be submitted at least seven days prior to the meeting date.
Genomics reports from UK HealthCare or external sources (Foundation, MATCH, etc.) can be submitted.
A patient's genomic report is required for case submission. Please see how to order a genomic report through UK HealthCare under Order a Genomic Report below.
If you already have a genomic report, fill out the case submission form online, or download the form below.
The patient’s genomic report can be sent to MTB by email.
When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.
Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed and/or mailed or uploaded into the electronic health record per the preference of the submitting physician. Specify method of results reporting on the case submission form.
Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.
Order a Genomic Report
Genomic reports can be ordered through the Clinical Molecular and Genomic Pathology department. There is a comprehensive solid tumor panel, some gene-specific hematological panels as well as a larger hematological malignancy panel. Please see the information forms below on the methodology of the panels and what genes are included in the panels.
To order a genomic report, the clinical staff must:
- Fill out the Requisition Form.
- Send tissue blocks to the address listed on the form: 800 Rose St. HA619, Lexington, KY 40536-0293
If you have any questions about ordering a genomic panel for your patient, please contact the Clinical Molecular and Genomic Pathology department at (859) 323-5327 or email@example.com.
Solid tumor panels:
Hematologic Malignancy Panels:
The Molecular Tumor Board currently has two prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.
- Part 1: A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
- Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.
Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.
Guidance documents are used to establish guidelines for Molecular Tumor Board (MTB) recommendations for advanced cancer.
MTB guidance documents will be made available to download below.
Download Guidance MTB Documents
Reference documents are used to aid Molecular Tumor Board members in meeting discussions and advanced care recommendations.
MTB reference documents will be made available for download below on this page.
Download Reference MTB Documents
Watch MTB presentations
- Clinical Update on Breast Cancer: When to Test and Emerging Therapies
- Clinical Update on GI Cancer: When to Test and Emerging Therapies
- Clinical Update on Lung Cancer: When to Test and Emerging Therapies
- Next Generation Sequencing: What They Are & When to Order Them
- Intro to MCC Clinical Practice Guidelines
Jill Kolesar, PharmD
Professor, College of Pharmacy
Department of Pharmacy Practice and Science
Chandler Park, MD, FACP
Research Medical Director at Hardin Memorial Hospital, Central Kentucky Region
UK Markey Cancer Center Research Network
Rachel Ware Miller, MD
Associate Professor, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Abigail Anderson, PhD,